CN101880280B - 双环嘧啶酮以及其应用 - Google Patents

双环嘧啶酮以及其应用 Download PDF

Info

Publication number
CN101880280B
CN101880280B CN201010148170.6A CN201010148170A CN101880280B CN 101880280 B CN101880280 B CN 101880280B CN 201010148170 A CN201010148170 A CN 201010148170A CN 101880280 B CN101880280 B CN 101880280B
Authority
CN
China
Prior art keywords
hydroxy
oxo
pyrimidine
nmr
preparation
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CN201010148170.6A
Other languages
English (en)
Chinese (zh)
Other versions
CN101880280A (zh
Inventor
埃里克·戴尔·琼斯
乔纳森·艾伦·维克多·科茨
戴维·伊恩·罗兹
约翰·约瑟夫·戴德曼
尼古拉斯·安德鲁·范德格拉夫
莉萨·简·温菲尔德
内尔纳·天通
威廉·伊萨
尼尔·乔依
凯瑟琳·麦克法兰
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Tali Digital Ltd
Shanghai Institute of Organic Chemistry
Original Assignee
Avexa Ltd
Shanghai Institute of Organic Chemistry
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from AU2006907283A external-priority patent/AU2006907283A0/en
Application filed by Avexa Ltd, Shanghai Institute of Organic Chemistry filed Critical Avexa Ltd
Publication of CN101880280A publication Critical patent/CN101880280A/zh
Application granted granted Critical
Publication of CN101880280B publication Critical patent/CN101880280B/zh
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/60—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings condensed with carbocyclic rings or ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D275/00—Heterocyclic compounds containing 1,2-thiazole or hydrogenated 1,2-thiazole rings
    • C07D275/04—Heterocyclic compounds containing 1,2-thiazole or hydrogenated 1,2-thiazole rings condensed with carbocyclic rings or ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Pulmonology (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
CN201010148170.6A 2006-12-22 2007-12-21 双环嘧啶酮以及其应用 Expired - Fee Related CN101880280B (zh)

Applications Claiming Priority (8)

Application Number Priority Date Filing Date Title
AU2006907283 2006-12-22
AU2006907283A AU2006907283A0 (en) 2006-12-22 Bicyclic pyrimidinones and uses thereof
AU2007902479 2007-05-09
AU2007902479A AU2007902479A0 (en) 2007-05-09 Bicyclic pyrimidinones and uses thereof (2)
AU2007903401 2007-06-25
AU2007903401A AU2007903401A0 (en) 2007-06-25 Bicyclic pyrimidinodes and uses thereof (3)
AU2007904114 2007-07-31
AU2007904114A AU2007904114A0 (en) 2007-07-31 Bicyclic pyrimidinones and uses thereof (4)

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
CN200780051562.7A Division CN101627019B (zh) 2006-12-22 2007-12-21 双环嘧啶酮以及其应用

Publications (2)

Publication Number Publication Date
CN101880280A CN101880280A (zh) 2010-11-10
CN101880280B true CN101880280B (zh) 2014-07-16

Family

ID=39562030

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201010148170.6A Expired - Fee Related CN101880280B (zh) 2006-12-22 2007-12-21 双环嘧啶酮以及其应用

Country Status (15)

Country Link
US (3) US8143268B2 (cg-RX-API-DMAC10.html)
EP (2) EP2114903B1 (cg-RX-API-DMAC10.html)
JP (2) JP5208962B2 (cg-RX-API-DMAC10.html)
KR (2) KR20090097194A (cg-RX-API-DMAC10.html)
CN (1) CN101880280B (cg-RX-API-DMAC10.html)
AR (2) AR064517A1 (cg-RX-API-DMAC10.html)
AT (1) ATE496898T1 (cg-RX-API-DMAC10.html)
AU (2) AU2007336703B9 (cg-RX-API-DMAC10.html)
BR (2) BRPI0720564A2 (cg-RX-API-DMAC10.html)
CA (1) CA2673183C (cg-RX-API-DMAC10.html)
DE (1) DE602007012308D1 (cg-RX-API-DMAC10.html)
DK (1) DK2114903T3 (cg-RX-API-DMAC10.html)
MX (1) MX2009006764A (cg-RX-API-DMAC10.html)
NZ (1) NZ577491A (cg-RX-API-DMAC10.html)
WO (1) WO2008077188A1 (cg-RX-API-DMAC10.html)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8318732B2 (en) * 2008-07-02 2012-11-27 Avexa Limited Compounds having antiviral properties
WO2010000031A1 (en) * 2008-07-02 2010-01-07 Avexa Limited Imidazopyrimidinones and uses thereof
EP2247601B1 (en) * 2008-07-02 2013-04-10 Avexa Limited Thiazopyrimidinones and uses thereof
CN102336751A (zh) * 2010-07-16 2012-02-01 爱维艾珂瑟有限公司 新型抗病毒剂
CN105764904B (zh) 2013-09-12 2020-02-11 詹森生物制药有限公司 氮杂-吡啶酮化合物及其用途
WO2015105657A1 (en) * 2013-12-19 2015-07-16 Ptc Therapeutics, Inc. Methods for modulating the amount of rna transcripts
WO2016145103A1 (en) 2015-03-11 2016-09-15 Alios Biopharma, Inc. Aza-pyridone compounds and uses thereof
EP3310169B1 (en) 2015-05-30 2023-05-17 PTC Therapeutics, Inc. Methods for modulating rna splicing
CA3119019C (en) 2015-12-10 2024-06-11 Ptc Therapeutics, Inc. Compounds and methods for treating huntington's disease
JP2019535789A (ja) 2016-11-28 2019-12-12 ピーティーシー セラピューティクス,インコーポレーテッド Rnaスプライシングを調節する方法
EP4151627A1 (en) 2017-06-05 2023-03-22 PTC Therapeutics, Inc. Compounds for treating huntington's disease
CN111372611A (zh) 2017-06-14 2020-07-03 Ptc医疗公司 修饰rna剪接的方法
CN111163838B (zh) 2017-06-28 2023-03-28 Ptc医疗公司 用于治疗亨廷顿氏病的方法
CN111182898B (zh) 2017-06-28 2024-04-16 Ptc医疗公司 用于治疗亨廷顿氏病的方法
BR112020019373A2 (pt) 2018-03-27 2020-12-29 Ptc Therapeutics, Inc. Compostos para o tratamento da doença de hutington
IL279688B2 (en) 2018-06-27 2025-01-01 Ptc Therapeutics Inc Heterocyclic and heteroaryl compounds for the treatment of Huntington's disease
WO2020005882A1 (en) 2018-06-27 2020-01-02 Ptc Therapeutics, Inc. Heteroaryl compounds for treating huntington's disease
KR20210038845A (ko) 2018-06-27 2021-04-08 피티씨 테라퓨틱스, 인크. 헌팅턴병 치료를 위한 헤테로아릴 화합물
CA3139821A1 (en) 2019-05-13 2020-11-19 Ptc Therapeutics, Inc. Compounds for treating huntington's disease
US12195458B2 (en) 2019-12-02 2025-01-14 Storm Therapeutics Limited Polyheterocyclic compounds as METTL3 inhibitors
US12070445B2 (en) * 2021-08-27 2024-08-27 Wisconsin Alumni Research Foundation System and assay for monitoring production/release of membrane-lytic toxins in bacteria and compounds for modulating same

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002044141A2 (en) 2000-09-20 2002-06-06 Schering Corporation Substituted imidazoles as dual histamine h1 and h3 agonists or antagonists
US7176220B2 (en) 2002-11-20 2007-02-13 Japan Tobacco Inc. 4-oxoquinoline compound and use thereof as pharmaceutical agent
ATE435222T1 (de) 2003-12-18 2009-07-15 Tibotec Pharm Ltd Aminobenzimidazole und benzimidazole als inhibitoren der replikation von respiratory syncytial virus
TW200526635A (en) 2003-12-22 2005-08-16 Shionogi & Co Hydroxypyrimidinone derivative having HIV integrase inhibitory activity
MX2007004403A (es) 2004-10-12 2007-04-27 Astrazeneca Ab Derivados de quinazolina.
WO2006103399A1 (en) 2005-03-31 2006-10-05 Istituto Di Ricerche Di Biologia Molecolare P Angeletti Spa Hiv integrase inhibitors
JP5094725B2 (ja) 2005-10-04 2012-12-12 イステイチユート・デイ・リチエルケ・デイ・ビオロジア・モレコラーレ・ピ・アンジエレツテイ・エツセ・エルレ・エルレ Hivインテグラーゼ阻害剤

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
M. Tisler et al..An improved synthesis of dimethyl diacetoxyfumarate and its condensation with heterocyclic amines.《Organic Preparations and Procedures International》.1990,第22卷(第4期),532-534. *

Also Published As

Publication number Publication date
AU2007336703B9 (en) 2014-03-27
AU2010201160A1 (en) 2010-04-15
JP2010513322A (ja) 2010-04-30
EP2114903A1 (en) 2009-11-11
MX2009006764A (es) 2009-11-26
AR077043A2 (es) 2011-07-27
JP2010222370A (ja) 2010-10-07
CN101880280A (zh) 2010-11-10
WO2008077188A1 (en) 2008-07-03
US20120232035A1 (en) 2012-09-13
EP2114903B1 (en) 2011-01-26
US20100168063A1 (en) 2010-07-01
EP2269992A1 (en) 2011-01-05
BRPI0720564A2 (pt) 2011-08-16
ATE496898T1 (de) 2011-02-15
AR064517A1 (es) 2009-04-08
US8859563B2 (en) 2014-10-14
KR20090097194A (ko) 2009-09-15
BRPI0722411A2 (pt) 2012-06-05
US8207334B2 (en) 2012-06-26
KR20100049698A (ko) 2010-05-12
CA2673183A1 (en) 2008-07-03
EP2114903A4 (en) 2009-12-30
AU2007336703B2 (en) 2012-04-12
HK1131615A1 (en) 2010-01-29
DK2114903T3 (da) 2011-04-18
DE602007012308D1 (de) 2011-03-10
US8143268B2 (en) 2012-03-27
US20110009366A1 (en) 2011-01-13
NZ577491A (en) 2011-06-30
JP5208962B2 (ja) 2013-06-12
AU2007336703A1 (en) 2008-07-03
CA2673183C (en) 2014-06-10

Similar Documents

Publication Publication Date Title
CN101880280A (zh) 双环嘧啶酮以及其应用
CN102143962B (zh) 具有抗病毒特性的化合物
BRPI0719361A2 (pt) Composto ou um sal farmaceuticamente aceitável do mesmo, composição farmacêutica, uso de um composto ou de um sal farmaceuticamente aceitável do mesmo, métodos para melhorar a qualidade do sono em um paciente mamífero, para tratar insônia em um paciente mamífero e para tratar ou controlar obesidade em um paciente mamífero
WO2003080581A1 (en) Phenanthridinones as parp inhibitors
WO2022022680A1 (zh) 含氮并环类衍生物抑制剂、其制备方法和应用
JP2003321472A (ja) Grk阻害剤
CN101627028A (zh) 作为食欲素受体拮抗剂的取代的二氮杂环庚烷化合物
JP2020531593A (ja) Mystファミリーのkat阻害剤として作用する縮合[1,2,4]チアジアジン誘導体
JP2023544157A (ja) Hsd17b13阻害剤及びその使用
CN100577663C (zh) 稠合杂环型激酶抑制剂
TW202513045A (zh) Parg抑制劑
CN101627019A (zh) 双环嘧啶酮以及其应用
ES2358550T3 (es) Pirimidinonas bicíclicas y sus usos.
HK1131615B (en) Bicyclic pyrimidinones and uses thereof
WO2024180103A1 (en) Sting agonists containing benzylic alcohol and benzylic amine functional groups
WO2025223550A1 (zh) 吡啶或吡嗪并三环化合物及其药用组合物和应用

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20140716

Termination date: 20151221

EXPY Termination of patent right or utility model